These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34462337)

  • 21. Baseline levels of dynamic CD4
    Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
    BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis.
    Melde M; Müller TM; Schneider I; Geppert CI; Mühl L; Besendorf L; Allner C; Becker E; Atreya I; Vitali F; Atreya R; Neurath MF; Zundler S
    Therap Adv Gastroenterol; 2021; 14():17562848211054707. PubMed ID: 34868349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vedolizumab Antagonizes MAdCAM-1-Dependent Human Placental Cytotrophoblast Adhesion and Invasion In Vitro.
    Blaisdell A; Zhou Y; Kattah MG; Fisher SJ; Mahadevan U
    Inflamm Bowel Dis; 2022 Aug; 28(8):1219-1228. PubMed ID: 35349682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms.
    Ungar B; Malickova K; Hanžel J; Abu Arisha M; Paul S; Rocha C; Ben Shatach Z; Abitbol CM; Haj Natour O; Selinger L; Yavzori M; Fudim E; Picard O; Shoval I; Eliakim R; Kopylov U; Magro F; Roblin X; Chowers Y; Drobne D; Lukas M; Ben Horin S
    J Crohns Colitis; 2021 Oct; 15(10):1707-1719. PubMed ID: 33837762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
    Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
    Front Immunol; 2018; 9():1700. PubMed ID: 30131801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
    Lamb CA; O'Byrne S; Keir ME; Butcher EC
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vedolizumab for the treatment of inflammatory bowel disease.
    Haddley K
    Drugs Today (Barc); 2014 Apr; 50(4):309-19. PubMed ID: 24918648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A product review of vedolizumab in inflammatory bowel disease.
    Battat R; Dulai PS; Jairath V; Vande Casteele N
    Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Responsiveness to Vedolizumab Therapy in Ulcerative Colitis is Associated With Alterations in Immune Cell-Cell Communications.
    Hsu P; Choi EJ; Patel SA; Wong WH; Olvera JG; Yao P; Liu YC; Tsai MS; Wang W; Boland BS; Chang JT
    Inflamm Bowel Dis; 2023 Oct; 29(10):1602-1612. PubMed ID: 37235748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
    Saruta M; Papadakis KA
    Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
    Jovani M; Danese S
    Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-β7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing.
    Sommer K; Heidbreder K; Kreiss L; Dedden M; Paap EM; Wiendl M; Becker E; Atreya R; Müller TM; Atreya I; Waldner M; Schürmann S; Friedrich O; Neurath MF; Zundler S
    Clin Transl Med; 2023 Apr; 13(4):e1233. PubMed ID: 37029786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.
    Lord JD; Long SA; Shows DM; Thorpe J; Schwedhelm K; Chen J; Kita M; Buckner JH
    Clin Immunol; 2018 Aug; 193():24-32. PubMed ID: 29842945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.
    Zundler S; Neurath MF
    Inflamm Bowel Dis; 2017 Apr; 23(4):617-627. PubMed ID: 28296823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.
    Milch C; Wyant T; Xu J; Parikh A; Kent W; Fox I; Berger J
    J Neuroimmunol; 2013 Nov; 264(1-2):123-6. PubMed ID: 24067534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vedolizumab-mediated integrin α4β7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice.
    Ling L; Wu T; To KKW; Cheung KW; Lui KOL; Niu M; Lam KS; Wang CC; Li J; Wang H; Yuen KY; Chen Z
    AIDS; 2019 Mar; 33(4):F1-F12. PubMed ID: 30829743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis.
    de Krijger M; Wildenberg ME; de Jonge WJ; Ponsioen CY
    J Hepatol; 2019 Sep; 71(3):603-615. PubMed ID: 31108158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related Enteropathy.
    Akhtar HJ; Nguyen TM; Ma C; Jairath V
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e614-e623. PubMed ID: 33618025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
    Amiot A; Grimaud JC; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Gagniere C; Vuitton L; Viennot S; Aubourg A; Pelletier AL; Bouguen G; Abitbol V; Bouhnik Y; ;
    Clin Gastroenterol Hepatol; 2016 Nov; 14(11):1593-1601.e2. PubMed ID: 26917043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vedolizumab in the treatment of Crohn's disease.
    Tarabar D; Hirsch A; Rubin DT
    Expert Rev Gastroenterol Hepatol; 2016; 10(3):283-90. PubMed ID: 26810276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.